Adicet Bio offers a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseases, trading below cash value with a pivotal readout imminent. Early prula-cel data in lupus nephritis showed 50% complete renal response and clean safety, supporting the curative CAR-T thesis versus chronic biologics. The upcoming 3Q 2026 readout on 22 patients is a binary catalyst; durability and long-term remission are critical for upside realization.
Avis Budget's Q2 earnings miss exposed soft rental demand, while fleet cuts, record utilization and reaffirmed 2026 EBITDA guidance supported margins.
Avis Budget's efficiency gains are lifting profits, but weak liquidity, high leverage and a premium valuation argue for patience.
| Transportation Infrastructure Industry | Industrials Sector | Brian J. Choi CEO | XETRA Exchange | US0537741052 ISIN |
| US Country | 21,000 Employees | 21 Dec 2023 Last Dividend | 5 Sep 2006 Last Split | 12 Jan 1990 IPO Date |
Avis Budget Group, Inc. operates as a comprehensive provider of mobility solutions, catering to both business and consumer needs across various geographical realms including the Americas, Europe, the Middle East and Africa, Asia, and Australasia. With its roots tracing back to 1946 and a rebranding from Cendant Corporation in September 2006, this entity has grown into a formidable platoon in the mobility services domain, headquartered in Parsippany, New Jersey. Through its diverse portfolio of brands — Avis, Budget, Zipcar, and several others — the company is strategically positioned across different market segments, from premium commercial and leisure travel to value-conscious consumer segments.
Avis Budget Group, Inc. boasts a wide range of mobility solutions and ancillary products and services, addressing the varied necessities of its clientele. Here's an overview of their primary offerings: